Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis

被引：116

作者：

Zamvil, SS ^{[1
]}

Steinman, L

机构：

[1] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA

[2] Stanford Univ, Beckman Ctr Mol Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA

来源：

NEURON | 2003年 / 38卷 / 05期

关键词：

D O I：

10.1016/S0896-6273(03)00326-X

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Multiple sclerosis (MS) is an autoimmune central nervous system (CNS) demyelinating disease that causes relapsing and chronic neurologic impairment. Recent observations have altered certain traditional concepts regarding MS pathogenesis. A greater diversity of cell types and molecules involved in MS is now evident. While remyelination can occur during the early inflammatory phase when damage may be reversible, it is impaired in the later stages, which involve axonal death. These observations have important therapeutic implications.

引用

页码：685 / 688

页数：4

共 25 条

[1] The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease [J].

Chabas, D ;

Baranzini, SE ;

Mitchell, D ;

Bernard, CCA ;

Rittling, SR ;

Denhardt, DT ;

Sobel, RA ;

Lock, C ;

Karpuj, M ;

Pedotti, R ;

Heller, R ;

Oksenberg, JR ;

Steinman, L .

SCIENCE, 2001, 294 (5547) :1731-1735

[2] Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis [J].

Chang, A ;

Tourtellotte, WW ;

Rudick, R ;

Trapp, BD .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (03) :165-173

[3] Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis [J].

Duda, PW ;

Schmied, MC ;

Cook, SL ;

Krieger, JI ;

Hafler, DA .

JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (07) :967-976

[4] Identification of autoantibodies associated with myelin damage in multiple sclerosis [J].

Genain, CP ;

Cannella, B ;

Hauser, SL ;

Raine, CS .

NATURE MEDICINE, 1999, 5 (02) :170-175

[5] A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex [J].

Haines, JL ;

TerMinassian, M ;

Bazyk, A ;

Gusella, JF ;

Kim, DJ ;

Terwedow, H ;

PericakVance, MA ;

Rimmler, JB ;

Haynes, CS ;

Roses, AD ;

Lee, A ;

Shaner, B ;

Menold, M ;

Seboun, E ;

Fitoussi, RP ;

Gartioux, C ;

Reyes, C ;

Ribierre, F ;

Gyapay, G ;

Weissenbach, J ;

Hauser, SL ;

Goodkin, DE ;

Lincoln, R ;

Usuku, K ;

GarciaMerino, A ;

Gatto, N ;

Young, S ;

Oksenberg, JR .

NATURE GENETICS, 1996, 13 (04) :469-471

[6] Myelin failure in multiple sclerosis: Breaking the spell of Notch [J].

Hohlfeld, R .

NATURE MEDICINE, 2002, 8 (10) :1075-1076

[7] A pathogenic role for myelin-specific CD8+ T cells in a model for multiple sclerosis [J].

Huseby, ES ;

Liggitt, D ;

Brabb, T ;

Schnabel, B ;

Öhlén, C ;

Goverman, J .

JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 194 (05) :669-676

[8] Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial [J].

Kappos, L ;

Comi, G ;

Panitch, H ;

Oger, J ;

Antel, J ;

Conlon, P ;

Steinman, L .

NATURE MEDICINE, 2000, 6 (10) :1176-1182

[9] Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis [J].

Lock, C ;

Hermans, G ;

Pedotti, R ;

Brendolan, A ;

Schadt, E ;

Garren, H ;

Langer-Gould, A ;

Strober, S ;

Cannella, B ;

Allard, J ;

Klonowski, P ;

Austin, A ;

Lad, N ;

Kaminski, N ;

Galli, SJ ;

Oksenberg, JR ;

Raine, CS ;

Heller, R ;

Steinman, L .

NATURE MEDICINE, 2002, 8 (05) :500-508

[10]

Lucchinetti C, 2000, ANN NEUROL, V47, P707, DOI 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO

← 1 2 3 →